PET has been used to examine changes in neurotransmitter concentrations in the living brain. Pioneering PET studies on the dopamine system have used D 2 and D 3 receptor (D 2 /D 3 ) antagonists such as 11 C-raclopride. However, more recently developed agonist radioligands have shown enhanced sensitivity to endogenous dopamine. A limitation of available agonist radioligands is that they incorporate the short-lived radioisotope 11 C. In the current study, we developed the 18 F-labeled D 2 /D 3 receptor agonist (R)-(−)-2-18 Ffluoroethoxy-N-n-propylnorapomorphine ( 18 F-MCL-524). Methods: In total, 10 PET measurements were conducted on 5 cynomolgus monkeys. Initially, the binding of 18 F-MCL-524 was compared with that of 11 C-MNPA in 3 monkeys. Second, the specificity of 18 F-MCL-524 binding was examined in pretreatment studies using raclopride (1.0 mg/kg) and D-amphetamine (1.0 mg/kg). Third, a preliminary kinetic analysis was performed using the radiometabolitecorrected arterial input function of the baseline studies. Finally, 2 whole-body PET measurements were conducted to evaluate biodistribution and radiation dosimetry after intravenous injection of 18 F-MCL-524. Results: 18 F-MCL-524 entered the brain and provided striatum-to-cerebellum ratios suitable for reliable quantification of receptor binding using the multilinear reference tissue model. Mean striatal nondisplaceable binding potential (BP ND ) values were 2.0 after injection of 18 F-MCL-524 and 1.4 after 11 C-MNPA. The ratio of the BP ND values of 18 F-MCL-524 and 11 C-MNPA was 1.5 across striatal subregions. After administration of raclopride and Damphetamine, the 18 F-MCL-524 BP ND values were reduced by 89% and 56%, respectively. Preliminary kinetic analysis demonstrated that BP ND values obtained with the 1-tissue-and 2-tissue-compartment models were similar to values obtained with the multilinear reference tissue model. Estimated radiation doses were highest for gallbladder (0.27 mSv/MBq), upper large intestine (0.19 mSv/ MBq), and small intestine (0.17 mSv/MBq). The estimated effective dose was 0.035 mSv/MBq. Conclusion: The 18 F-labeled agonist 18 F-MCL-524 appears suitable for quantification of D 2 /D 3 receptor binding in vivo, and the results encourage extension to human studies. The longer half-life of 18 F makes 18 F-MCL-524 attractive for studies on modulation of the dopamine concentration-for example, in combination with simultaneous measurement of changes in bloodoxygen-level-dependent signal using bimodal PET/functional MRI.
mine receptors exist in 2 affinity states for agonists (1) , similar to other G protein-coupled receptors. The 2 affinity states are considered interconvertible, with the high-affinity state corresponding to the functional, G protein-coupled state of the receptor (2) . PET studies of dopamine D 2 and D 3 receptors (D 2 /D 3 ) have since long predominantly been conducted using antagonists, such as 11 Craclopride. However, antagonists bind with equal affinity to the 2 affinity states of the receptor and do not provide information on the fraction of receptors in the high-affinity state. To overcome this limitation, agonist radioligands have more recently been developed (3), including 11 C-N-propylnorapomorphine ( 11 C-NPA) (4), 11 C-MNPA (5), and 11 C-4-propyl-9-hydroxynaphthoxazine (6) . A reported advantage of these agonist radioligands is the enhanced sensitivity to amphetamine-induced changes in dopamine concentration when compared with 11 C-raclopride (7, 8) .
A limitation of the currently available agonist radioligands is the labeling with the relatively short-lived radioisotope 11 C (halflife, 20.3 min). Radiolabeling of an agonist with a longer-lived radioisotope, such as 18 F (half-life, 109.8 min), may provide several advantages. First, an 18 F-labeled ligand may favorably be used with bolus-infusion techniques, which allow quantification of binding potential at baseline and at a series of dopamine concentration-altering conditions in a single PET measurement. This paradigm is particularly attractive for application in the recently developed PET/functional MRI systems that allow for simultaneous measurements of changes in neurotransmitter concentration and blood-oxygen-level-dependent signal (9) . Second, the longer halflife of 18 F will allow for studies evaluating the acute and prolonged effects of a dopamine-related change in receptor binding, thereby having potential to disentangle return of dopamine levels to baseline from receptor internalization (10) . Third, the longer half-life of 18 F enhances the feasibility of radioligands to be used in clinical centers where no cyclotron is available for on-site radioligand production. An 18 F-labeled radioligand with high sensitivity to the endogenous dopamine concentration may therefore have wide utility. Development of 18 F-labeled D 2 /D 3 receptor agonist radioligands has previously been reported, but with only limited success (11) . 18 F-analogs of successful 11 C-labeled aporphine and naphthoxazine scaffold-based radioligands have not been promising (12, 13) , because the introduction of 18 F into the N-alkyl chain decreases binding affinity significantly. Perhaps the most promising radioligand so far is (R,S)-2-(N-propyl-N-59-18 F-fluoropentyl)amino-5-hydroxytetralin, though the reported striatal-to-cerebellum binding ratios were only 2.0 in monkeys (14) . Follow-up studies with this radioligand have so far not been reported.
In the current study, we radiolabeled the aporphine (R)-(2)-2-18 Ffluoroethoxy-N-n-propylnorapomorphine ( 18 F-MCL-524) (Fig. 1) . This compound has nanomolar affinity in vitro to the D 2 receptor in a state of high affinity (D 2 high ) (3.7 nM) (15) , and the radionuclide can be remotely introduced into the substituent at the 2-position. After radiosynthesis, 18 F-MCL-524 was evaluated by PET in cynomolgus monkeys. We compared the binding of 18 F-MCL-524 to 11 C-MNPA and conducted pretreatment studies with raclopride and D-amphetamine to confirm specific binding to the D 2 /D 3 receptors and dopamine sensitivity. A preliminary kinetic analysis was performed using the radiometabolite-corrected arterial input function. Finally, 2 whole-body PET examinations were conducted to obtain dosimetry estimates in preparation for future human studies.
MATERIALS AND METHODS

Preparation of Radioligands
The standard MCL-524 was prepared according to previously reported methods (15) . The synthesis of the corresponding tosylated precursor MCL-556 is described in the supplemental information (supplemental materials are available at http://jnm.snmjournals.org). All other chemicals and materials were obtained from commercial sources, were of analytic grade, and were used as received. 18 F-MCL-524 was prepared in 2 steps. Direct fluorination of MCL-556 was followed by deprotection of the catechol moiety (supplemental information). 11 C-MNPA was prepared using previously described procedures (16) .
PET Studies on Nonhuman Primates
The study was approved by the Animal Research Ethical Committee of the Northern Stockholm region (diarienummer N386/09, N399/ 08, and N452/11) and was performed according to local (diarienummer 4820/06-600) and international guidelines (17) . Five cynomolgus monkeys (Macaca fascicularis) (M1-M5), weighing 4-8 kg, were included in the study. Anesthesia and experimental procedures were similar to those reported before (18) . PET measurements of the brain or whole body were conducted using a high-resolution research tomograph (HRRT; Siemens Molecular Imaging) or the Biograph TruePoint TrueV PET/CT system (Siemens Medical Solutions), respectively, and followed previously reported procedures (18) (19) (20) .
PET Studies Using HRRT. On each of 3 experimental days, baseline PET measurements after injection of 18 F-MCL-524 and 11 C-MNPA were performed to allow for a direct comparison of the 2 radioligands. PET measurements with 11 C-MNPA were conducted 2.5 h before injection of 18 F-MCL-524 in 3 cynomolgus monkeys (M1-M3).
To characterize the specificity and dopamine sensitivity of 18 F-MCL-524 receptor binding, pretreatment studies were performed using the D 2 /D 3 receptor antagonist raclopride (in M1) and the dopaminereleasing drug D-amphetamine (in M2), respectively. The pretreatment studies were performed on monkeys (M1 and M2) for which baseline data had been obtained at least 1 mo earlier as described above. Raclopride (1.0 mg/kg, tartrate salt, in phosphate-buffered saline) was infused intravenously over 10 min, starting 23 min before the injection of 18 F-MCL-524. D-amphetamine (1.0 mg/kg, sulfate salt, in phosphate-buffered saline) was infused intravenously over 15 min, starting 29 min before the injection of 18 F-MCL-524.
To allow for a preliminary assessment of the quantification methods suitable for 18 F-MCL-524, arterial blood sampling was included in the 3 baseline PET studies described above. A cannula was inserted in the femoral artery or an artery of the lower limb, and arterial blood was collected continuously for 3 min using an automated blood sampling system (Allogg AB) at a speed of 3.0 mL/min. Blood samples (1.0-3.0 mL) were drawn at 0.5, 1.0, 1.5, 2.0, 3.0, 6.0, and 8.0 min for blood and plasma radioactivity and at 2.5, 5.0, 15, 30, 45, 60, 90, and 120 min for metabolite correction. One blood sample was taken before radioligand injection for determination of radioligand binding to plasma proteins.
Unchanged radioligand and radiometabolite fractions in plasma were determined using a previously described reversed-phase highperformance liquid chromatography method (18) The free fraction, f p , in plasma was estimated using a previously reported ultrafiltration method (18) . PET Studies Using PET/CT. For determination of biodistribution and radiation dosimetry, 2 different cynomolgus monkeys (M4 and M5) were evaluated according to previously reported procedures (19) using the Biograph PET/CT system after intravenous injection of 18 F-MCL-524. 
Image Analysis and Quantification
All image analyses and PET quantification were performed using PMOD (version 3.308; PMOD Technologies Ltd.).
PET Studies Using HRRT. An average PET image (mean of 0-12 min) was automatically coregistered to an MR image. Volumes of interest were delineated on the individual template MR images for the caudate nucleus, cerebellum, midbrain, putamen, thalamus, ventral striatum, and whole brain. The volume of interest for the cerebellum included only cerebellar hemispheres. The striatum was defined as the volume-weighted mean of the striatal subregions. Decay-corrected time-activity curves for all regions were plotted over time, and radioactivity concentrations were expressed as the standardized uptake value (gÁcm 23 ).
Regional nondisplaceable binding potential (BP ND ) values were calculated with the multilinear reference tissue model (MRTM) (equilibrium time, 0 min) using the cerebellum as the reference region (21) . In the preliminary kinetic analysis, the time-activity curves were interpreted using the 1-tissue-compartment model (1TCM) and the 2-tissuecompartment model (2TCM). Graphical analysis (GA) was performed by using the Logan plot and with an equilibrium time of 21 min (22) . The outcome parameters were the total distribution volume (V T ) and the BP ND obtained using the cerebellum as the reference region (23) . BP ND values were also calculated for the tissue compartment models and GA as (striatal V T /cerebellum V T 2 1) and compared with the BP ND values obtained with the MRTM (21) .
The radiometabolite-corrected plasma concentration of 18 F-MCL-524 was used as the input function. The relative blood volume in brain was defined as 0.05. The Akaike information criterion and F statistics of the sum of squared residuals were used to compare the fits of the 1TCM and 2TCM analyses. The identifiability of the kinetic parameters was assessed using the SE coefficients of variation. To assess the time stability of V T and BP ND values, the effect of the duration of the PET measurement was evaluated by truncating the PET datasets from 120 to 30 min.
PET Studies Using PET/CT. Volumes of interest were defined for the brain, parotid glands, thyroid gland, lungs, heart, liver, gallbladder, upper gastrointestinal tract (stomach and duodenum), lower gastrointestinal tract, spleen, kidneys, bladder, and bone (claviculae) using CT. The remainder was estimated by drawing a large volume of interest around the whole body and by subtracting the radioactivity measured in the individual organs. The regional radioactivity concentration in each of the 2 whole-body PET measurements was decay-corrected to the time of injection and expressed as percentage injected radioactivity and plotted versus time. Estimates of the absorbed radiation dose in humans were calculated using the OLINDA/EXM software. Percentages of injected radioactivity per organ were fitted using the SAAM II software (24) . Time integrals of activity (25) were then entered into the OLINDA/EXM software (26), using the adult male model. Activity was observed in the intestines and urinary bladder. Data for the bladder were fit to a retention function, as was done for the other organs. The number of disintegrations in the remainder of the body was assumed to be equal to 100% of the activity administered integrated to total decay of 18 F, minus the disintegrations in other organs.
RESULTS
Preparation of Radioligands
18 F-MCL-524 was obtained with a mean specific radioactivity of 226 GBq/mmol (range, 125-568 GBq/mmol) at the time of injection, corresponding to an injected mass of 0.34 mg (range, 0.10-0.47 mg). 18 F-MCL-524 was found to be stable for at least 2 h in the formulation prepared for injection. 11 C-MNPA was obtained with a specific radioactivity of more than 185 GBq/mmol, corresponding to an injected mass of less than 0.26 mg. The radiochemical purity for the injected radioligands was typically greater than 95%.
Comparison with 11 C-MNPA and Pretreatment Studies
After injection of 18 F-MCL-524, the radioactivity concentration was higher in the striatum and lower in the cerebellum than for 11 C-MNPA (Fig. 2) . The mean striatal BP ND values were 2.0 after injection of 18 F-MCL-524 and 1.4 after 11 C-MNPA. The ratio of the BP ND values of 18 F-MCL-524 and 11 C-MNPA was 1.5 across striatal subregions (Table 1) . 18 F-MCL-524 binding in the striatum, but not in the cerebellum, decreased after administration of raclopride (1.0 mg/kg) or D-amphetamine (1.0 mg/kg) (Fig. 3) . After administration of raclopride, the striatal BP ND was 0.25, which corresponds to an 89% reduction from baseline conditions. After D-amphetamine, the striatal BP ND decreased to 0.92, which corresponds to a 56% reduction from baseline conditions.
Radiometabolite Analyses and Preliminary Kinetic Analysis
A representative high-performance liquid radiochromatogram, obtained at 60 min after injection of 18 F-MCL-524, is displayed in Figure 4A . After injection of 18 F-MCL-524, several radiometabolite fractions could be measured during the time course of the PET measurement. All observed radiometabolite fractions had a retention time shorter than 18 F-MCL-524 (8.8 min). 18 F-MCL-524 was rapidly metabolized, and mean unchanged radioligand accounted for 50% of the plasma radioactivity at 5 min and 13% at 120 min after injection (Fig. 4B) . The mean f p was 0.07 for 18 F-MCL-524 and 0.10 for 11 C-MNPA at baseline conditions. After injection of 18 F-MCL-524, the radioactivity in plasma representing unchanged radioligand decreased rapidly (Fig. 4C) . The time-radioactivity curves for the cerebellum and striatum could be described with the 1TCM as well as the 2TCM (Fig.  4D) . The 1TCM was the preferred model for the striatum and cerebellum in all 3 monkeys, according to F statistics of the sum of squared residuals (P , 0.05) and a lower Akaike information criterion (Table 2 ; Fig. 4D ). Both models provided reliable estimates of V T values , except for the 2TCM analysis of the cerebellum in one monkey. Individual rate constants could be reliably identified only with the 1TCM (Table 2) . Mean V T values calculated by using the rate constants obtained from the 1TCM were 16.5 mLÁcm 23 for the striatum and 5.0 mLÁcm 23 for the cerebellum and similar when calculated with rate constants from the 2TCM ( Table 2 ). Mean striatal V T values were 7% lower when calculated with GA than when calculated with the 1TCM (Table 2) . Mean striatal BP ND values calculated with the 1TCM and GA were 2.3 and 2.1, respectively, compared with 2.0 obtained with the MRTM (Table  3) . BP ND values were reliably calculated with a PET duration of 60 min for the MRTM and 90 min for the 1TCM.
Whole-Body Distribution and Radiation Dosimetry
The uptake of radioactivity (percentage injected radioactivity) was highest in the lungs (20% at ;1 min), kidneys (9% at ;1 min), and liver (9% at ;9 min) and lower in the heart (2% at ;1 min) and bone (2% at ;1 min) (Figs. 5 and 6 ). 18 F-MCL-524 was eliminated mainly through the intestine, with the highest accumulation occurring at about 228 min in the upper gastrointestinal tract (31%), lower gastrointestinal tract (15%), gallbladder (7%), and urinary bladder (8%). Extrapolation to human dose estimates found that the largest absorbed dose was to the gallbladder, followed by the upper large intestine and small intestine. The average calculated effective dose was 0.035 mSv/MBq (Table 4) .
DISCUSSION
The aim of the current study was to develop an 18 F-labeled dopamine D 2 /D 3 receptor agonist radioligand. For this purpose, 18 F-MCL-524 was selected for radiolabeling on the basis of affinity in vitro to the D 2 high receptor. PET studies on monkeys demonstrated that 18 F-MCL-524 provides a binding signal that is similar to, or even higher than, the previously developed radioligand 11 C-MNPA. Blocking studies and preliminary kinetic analysis further supported the suitability of the radioligand properties of 18 F-MCL-524. The longer half-life of 18 F than of 11 C is a unique property of 18 F-MCL-524 in comparison to the already available 11 C-labeled agonist radioligands. 18 F-MCL-524 is thus an interesting candidate for future PET studies on dopamine modulation in preclinical or clinical settings. 18 F was introduced into the 2-position moiety of the aporphine scaffold. This approach is preferable to introduction of 18 F into the N-alkyl chain, because the latter has been shown to be detrimental for the affinity in vivo to the D 2 /D 3 receptor (12) .
Like the reference 11 C-labeled ligand MNPA (5.1 6 1.3 nM), MCL-524 has nanomolar (3.7 6 1.2 nM) affinity to the D 2 high receptor in vitro (15) . A direct comparison between the 2 radioligands in 3 cynomolgus monkeys demonstrated that 18 F-MCL-524 provides similar or even higher contrast between the striatum and the cerebellum.
The favorable comparison with 11 C-MNPA prompted a preliminary characterization of the specificity of binding. After administration of the selective reference D 2 /D 3 receptor antagonist raclopride, the binding of 18 F-MCL-524 was markedly reduced (89% of striatal BP ND values) to a degree similar to that previously reported for 11 C-MNPA (5). This observation supports the view that 18 F-MCL-524 binds specifically to D 2 /D 3 receptors in vivo. Administration of D-amphetamine reduced the striatal 18 F-MCL-524 binding by 56%, similar to that previously reported for 11 C-MNPA (27) , supporting the view that 18 F-MCL-524 has agonistic properties.
18 F-MCL-524 underwent a moderate rate of metabolism, and the parent fraction in plasma was about 23% at 30 min after injection, which is similar to that reported for 11 C-MNPA (28) and 11 C-NPA (29) . The observed radiometabolite fractions (Fig. 4A) eluted earlier from the reversed-phase column than 18 F-MCL-524, suggesting that the radiometabolites are more polar and therefore less likely to pass the blood-brain barrier. The mean f p of 18 F-MCL-524 was 0.07, which is sufficiently large to allow for reliable quantification of plasma protein binding in applied studies.
A radiometabolite-corrected arterial input function was obtained in 3 monkeys examined with 18 F-MCL-524. The obtained regional time-activity curves were evaluated using the 1TCM and 2TCM. It was anticipated that the cerebellum (negligible D 2 /D 3 receptor density) and striatum (high D 2 /D 3 receptor density) could be best described with the 1TCM and 2TCM, respectively. However, both regions could be described with the 1TCM, and the 2TCM was not statistically preferred. This observation is similar to that previously reported for 11 C-NPA (29) and may indicate that the 4 rate constants of the 2TCM share sufficient similarities to allow for the curves to be described by the 2 rate constants of the 1TCM.
BP ND values were calculated with the MRTM but were also estimated using GA and the tissue compartment models. BP ND values calculated with MRTM compared well with values of GA and the 1TCM, but the approximately 12%-14% underestimation by MRTM in comparison to the 1TCM may require further evaluation in human subjects. BP ND values were stable after 60 or 90 min using the MRTM or 1TCM, respectively. Altogether, and considering reference tissue model advantages such as the redundancy of arterial cannulation and lower variability, a reference region approach such as the MRTM may be appropriate for clinical studies. 18 F-MCL-524 provided striatal BP ND values that were approximately 50% higher than those for 11 C-MNPA. The relative ratio of 18 F-MCL-524/ 11 C-MNPA was similar across striatal subregions. When the higher fraction of D 3 receptors in the ventral striatum is considered, the similarity across subregions suggests that the radioligands have similar D 2 -versus-D 3 receptor selectivity.
To prepare for human studies, we performed whole-body dosimetry on monkeys to estimate the radiation exposure in humans.
Similar to reports for 11 C-MNPA and 11 C-NPA (28, 30) , the organ with the highest uptake was the gallbladder. The extrapolated effective dose of 18 in human studies in preparation for applied clinical studies on changes in striatal dopamine concentration. The longer half-life of 18 F makes 18 F-MCL-524 particularly attractive for future application in bimodal PET/functional MRI for simultaneous measurement of changes in dopamine concentration and blood-oxygenlevel-dependent signal.
DISCLOSURE
The costs of publication of this article were defrayed in part by the payment of page charges. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734. Financial support was received from the Branfman Family Foundation and T32-DA007252. No other potential conflict of interest relevant to this article was reported. 
